(Q46859831)

25 December 2017

title

Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides (English)

1 reference

25 December 2017

1 reference

3

1 reference

25 December 2017

author name string

Stefanie Andrea Erika Held

1

1 reference

25 December 2017

Katharina Maria Duchardt

2

1 reference

25 December 2017

Thomas Rückrich

4

1 reference

25 December 2017

Karin von Schwarzenberg

5

1 reference

25 December 2017

Anita Bringmann

6

1 reference

25 December 2017

Christian Kurts

7

1 reference

25 December 2017

Hansjörg Schild

8

1 reference

25 December 2017

Christoph Driessen

9

1 reference

25 December 2017

Peter Brossart

10

1 reference

25 December 2017

Annkristin Heine

11

1 reference

25 December 2017

publication date

25 November 2012

1 reference

25 December 2017

Cancer Immunology, Immunotherapy

published in

1 reference

25 December 2017

volume

62

1 reference

25 December 2017

issue

4

1 reference

25 December 2017

page(s)

715-726

1 reference

25 December 2017

https://scigraph.springernature.com/pub.10.1007/s00262-012-1373-7

exact match

0 references

cites work

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Acute leukaemia in bcr/abl transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Immunomodulatory effects of anti-angiogenic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Epithelial-specific transcription factor ESE-3 is involved in the development of monocyte-derived DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Quantitative analysis of prion-protein degradation by constitutive and immuno-20S proteasomes indicates differences correlated with disease susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Proteasome proteolytic profile is linked to Bcr-Abl expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Revealing the dynamics of the 20 S proteasome phosphoproteome: a combined CID and electron transfer dissociation approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1373-7

10.1007/S00262-012-1373-7

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017